Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review

被引：25

作者：

Zhao, Lingdi ^{[1
,2
]}

Yang, Yonghao ^{[1
,2
]}

Li, Wei ^{[1
,2
]}

Li, Tiepeng ^{[1
,2
]}

Gao, Quanli ^{[1
,2
]}

机构：

[1] Zhengzhou Univ, Affiliated Canc Hosp, Dept Immunotherapy, Zhengzhou, Henan, Peoples R China

[2] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 11期

关键词：

cytokine-release syndrome; Hodgkin's lymphoma; immunotherapy; refractory/relapsed; T-CELL THERAPY; HAPLOIDENTICAL DONOR TRANSPLANTATION; LYMPHOBLASTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; YOUNG-ADULTS; MULTICENTER; BIOMARKERS; MANAGEMENT; BLOCKADE; CHILDREN;

D O I：

10.2217/imt-2018-0025

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Hodgkin's lymphoma is a common malignant disease, especially among children in America. Although chemotherapy and radiotherapy are mainstay treatments for Hodgkin's lymphoma, a small portion of patient experiences relapsed or refractory diseases. Nivolumab provides an option for patients who experience relapsed or refractory disease, but adverse effects may occur. Here, we report a patient with relapsed/refractory Hodgkin's lymphoma who experienced cytokine-release syndrome after his first dose of nivolumab. The patient eventually experienced complete remission after his fifth dose of nivolumab. Cytokine-release syndrome might reflect good efficacy during treatment of relapsed/refractory Hodgkin's lymphoma with nivolumab. However, health care providers, should stay alert and take appropriate measures if adverse effects, such as cytokine-release syndrome, occur.

引用

页码：913 / 917

页数：5

共 30 条

[1] Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated [J].

Abboud, Ramzi ;

Keller, Jesse ;

Slade, Michael ;

DiPersio, John F. ;

Westervelt, Peter ;

Rettig, Michael P. ;

Meier, Stephanie ;

Fehniger, Todd A. ;

Abboud, Camille N. ;

Uy, Geoffrey L. ;

Vij, Ravi ;

Trinkaus, Kathryn M. ;

Schroeder, Mark A. ;

Romee, Rizwan .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) :1851-1860

[2] Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature [J].

Alig, Stefan K. ;

Dreyling, Martin ;

Seppi, Bettina ;

Aulinger, Benedikt ;

Witkowski, Lukas ;

Rieger, Christina T. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (06) :554-557

[3]

*AM CANC SOC, 2018, CANC FACTS FIG 2018

[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[5] Novel immunotherapies in lymphoid malignancies [J].

Batlevi, Connie Lee ;

Matsuki, Eri ;

Brentjens, Renier J. ;

Younes, Anas .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (01) :25-40

[6] Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD [J].

Bonfante, V ;

Santoro, A ;

Viviani, S ;

Devizzi, L ;

Balzarotti, M ;

Soncini, F ;

Zanini, M ;

Valagussa, P ;

Bonadonna, G .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :528-534

[7] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

[8] Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [J].

Davila, Marco L. ;

Riviere, Isabelle ;

Wang, Xiuyan ;

Bartido, Shirley ;

Park, Jae ;

Curran, Kevin ;

Chung, Stephen S. ;

Stefanski, Jolanta ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Fink, Mitsu ;

Shinglot, Himaly ;

Youssif, Maher ;

Satter, Mark ;

Wang, Yongzeng ;

Hosey, James ;

Quintanilla, Hilda ;

Halton, Elizabeth ;

Bernal, Yvette ;

Bouhassira, Diana C. G. ;

Arcila, Maria E. ;

Gonen, Mithat ;

Roboz, Gail J. ;

Maslak, Peter ;

Douer, Dan ;

Frattini, Mark G. ;

Giralt, Sergio ;

Sadelain, Michel ;

Brentjens, Renier .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[9] Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma [J].

Foran, Alexandra E. ;

Nadel, Helen R. ;

Lee, Anna F. ;

Savage, Kerry J. ;

Deyell, Rebecca J. .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (05) :E263-E266

[10] Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults [J].

Gardner, Rebecca A. ;

Finney, Olivia ;

Annesley, Colleen ;

Brakke, Hannah ;

Summers, Corinne ;

Leger, Kasey ;

Bleakley, Marie ;

Brown, Christopher ;

Mgebroff, Stephanie ;

Kelly-Spratt, Karen S. ;

Hoglund, Virginia ;

Lindgren, Catherine ;

Oron, Assaf P. ;

Li, Daniel ;

Riddell, Stanley R. ;

Park, Julie R. ;

Jensen, Michael C. .

BLOOD, 2017, 129 (25) :3322-3331

← 1 2 3 →